# Manus Biosynthesis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/manus-biosynthesis

- Industry: Chemicals
- Headquarters: Cambridge, US
- Website: www.manusbio.com
- Total disclosed funding: $19M
- Latest round: Series A (Jul 3, 2018)
- Investors on record: 2

## About

Manus Biosynthesis, Inc. is a biotechnology company focused on developing sustainable bioalternatives for traditional ingredients and materials, leveraging synthetic biology to address environmental challenges across various industries.Founded in 2011 and headquartered in Cambridge, US, Manus Bio specializes in creating bioalternatives aimed at replacing petrochemical-derived substances. The company has secured USD 75.00 mn in Series B funding, led by BBGI Public Company Limited in November 2020. CEO Ajikumar Parayil, the founder, has a history of entrepreneurial ventures in the biotech field. Manus Bio has executed a total of 4 deals since its inception.Manus Bio Inc. specializes in the development and production of bioalternatives, which are sustainable substitutes for traditional ingredients, materials, and chemicals sourced through environmentally harmful methods. The company’s core offerings leverage advanced synthetic biology and microbial cell factories to create a range of products that meet the needs of various industries, including food and beverage, cosmetics, and pharmaceuticals. Their focus on replacing petrochemical-derived substances with bio-based options addresses pressing environmental concerns and aims to enhance supply security for their clients. Manus Bio's flagship products include stevia Reb M, showcased in their partnerships with Tate & Lyle, and other sustainable BioIngredients designed to cater to an expanding market for eco-friendly raw materials. The company serves a global customer base, emphasizing markets in North America and South America, where they bring innovative solutions to manufacturers seeking to adopt more sustainable practices.Manus Bio generates revenue through strategic partnerships and direct business-to-business transactions with clients across various sectors. Their business model typically involves collaborations that enable companies to integrate bioalternatives into their existing product lines, allowing clients to benefit from more sustainable and efficient manufacturing processes. Revenue is driven by the sale of custom-engineered microbial solutions and bioingredients, with specific arrangements tailored to meet the needs of each client. The pricing structure is based on the scale and complexity of the products, as well as the contractual agreements established with larger manufacturers.Manus Biosynthesis, Inc. plans to accelerate its growth by launching new bioalternative products and expanding into additional markets, specifically increasing its presence in North America and South America by 2023. The recent Series B funding of USD 75.00 mn will support the development of innovative bioproducts and enhance operational capabilities for scaling production to meet growing market demand.

## Funding rounds

- Series A, Jul 3, 2018, $19M — NXT Ventures, 415 Investments

## Investors

- NXT Ventures (https://capitalatlas.ai/funds/nxt-ventures) — Series A
- 415 Investments — Series A